在3级脑膜瘤和p16/MTAP免疫组织化学中进行分子预测,以预测CDKN2A/B状态

Kira Tosefsky1, Karina Chornenka Martin2, Alexander D Rebchuk3

  • 1MD Undergraduate Program, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Neuro-oncology advances
|January 30, 2024
PubMed
概括

3级脑膜瘤的分子变化,包括TERT促进体突变和CDKN2A/B删除,显著影响患者的存活率. 针对p16和MTAP的免疫组织化学可以预测CDKN2A/B状态,有助于预后.